Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2024 Earnings Call Transcript
Operator: Good morning. And welcome to Ionis' First Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals Inc (IONS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,428,613 | $105,280,374 | 2.89% | |
| 2. | OrbiMed Advisors Samuel Isaly | 2,013,033 | $87,264,981 | -3% | 1.59% |
| 3. | ARK Investment Management Catherine D. Wood | 1,399,852 | $60,683,587 | -27% | 0.42% |
| 4. | Deep Track Capital David Kroin | 1,373,475 | $59,540,141 | +10% | 1.7% |
| 5. | 53,800,000 | $53,070,472 | -4% | 2.78% |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $40.29 | 16,000 | Director | 147,257 | 2024-06-17 | Filing | |
| $42.90 | 930 | Director | 0 | 2024-05-03 | Filing | |
| $42.55 | 1,070 | Director | 930 | 2024-05-03 | Filing | |
| $42.98 | 731 | Director | 2,000 | 2024-05-03 | Filing | |
| $42.59 | 1,269 | Director | 2,731 | 2024-05-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,520,872 | $1,088,740,914 | 0.08% | |
| 2. | 14,203,481 | $718,554,104 | 0.01% | |
| 3. | 9,057,530 | $458,220,441 | 0.01% | |
| 4. | 8,713,987 | $440,840,602 | 6.74% | |
| 5. | 4,707,480 | $238,151,403 | 0.2% |
News See All
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.78. Ionis Pharmaceuticals, Inc.
12 Most Promising Gene Editing Stocks According to Hedge Funds
In this piece, we will take a look at the 12 most promising gene editing stocks according to hedge funds.
5 Best Genomics Stocks To Buy Now
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a gene editing company developing treatments for cancer and immune system diseases.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q3 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Ionis' Third Quarter 2023 Financial Results Conference Call. As a reminder this call is being recorded. At this time, I would like to turn the call over Mr.
Top 5 Genomics Companies in the World
10x Genomics, Inc. (NASDAQ:TXG) is a backend genomics company that provides products that help with gene mapping.
16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Wood's Portfolio
In this article, we will take a look at the 16 best stocks to buy and hold for the next 15 years according to Cathie Wood's portfolio.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Ionis' Second Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Ionis First Quarter 2023 Financial Results Conference Call. As a reminder, this call is being recorded.
Billionaire Hedge Funds
